Fixed-combination and emerging glaucoma therapies

Bibliography

• QUIGLEY HA, BROMAN AT: The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. (2006) 90:262-267.
   PubMed Web of Science ®Google Scholar
• KASS MA, HEUER DK, HIGGINBOTHAM EJ et al.: The ocular hypertension treatment study. Arch. Ophthalmol. (2002) 120:701-713.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN DS, WILSON MR, LIEBMANN JM, FECHTNER RD, WEINREB RN: An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma. Am. J. Ophthalmol. (2004) 138:S19-S31.
   PubMed Web of Science ®Google Scholar
• WOODWARD DF: Glaucoma: novel agents and recent therapeutic advances. Exp. Opin. Ther. Patents (1996) 6:765-772.
   Web of Science ®Google Scholar
• SOMMER A, TIELSCH JM, KATZ J et al.: Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans: the Baltimore eye survey. Arch. Ophthalmol. (1991) 109:1090-1095.
   PubMed Web of Science ®Google Scholar
• MITCHELL P, SMITH W, ATTEBO K, HEALEY PR: Prevalence of open-angle glaucoma in Australia: the Blue Mountains eye study. Ophthalmology (1996) 103:1661-1669.
   PubMed Web of Science ®Google Scholar
• AGIS INVESTIGATORS: The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol. (2000) 130:429-440.
   PubMed Web of Science ®Google Scholar
• WEINREB RN, KHAW PT: Primary open-angle glaucoma. Lancet (2004) 363:1711-1720.
   PubMed Web of Science ®Google Scholar
• NOURI-MAHDAVI K, HOFFMAN D, COLEMAN AL et al.: Predictive factors for glaucomatous visual field progression in the advanced glaucoma intervention study. Ophthalmology (2004) 111:1627-1635.
   PubMed Web of Science ®Google Scholar
• BENGTSSON B, LESKE MC, HYMAN L, HEIJL A: EARLY MANIFEST GLAUCOMA TRIAL GROUP: Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology (2007) 114:205-209.
   PubMed Web of Science ®Google Scholar
• PALMBERG P: What is it about pressure that really matters in glaucoma? Ophthalmology (2007) 114:203-204.
   Google Scholar
• CAMRAS CB, WAX MB, RITCH R et al.: Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. Am. J. Ophthalmol. (1998) 126:390-399.
   PubMed Web of Science ®Google Scholar
• WHITCUP SM, CANTOR LB, VANDENBURGHAM, CHEN K, BIMATOPROST STUDY GROUP II: A randomised, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension. Br. J. Ophthalmol. (2003) 87:57-62.
   PubMed Web of Science ®Google Scholar
• KHARLAMB AB, KRAUSS AH, CHEN J et al.: Prostanoid EP4 receptor stimulation produces profound ocular hypotension that involves pressure dependent outflow. ARVO (2004):E-Abstract 1035.
   Google Scholar
• NILSSON SFE, DRECOLL E, LÜTJEN-DRECOLL E et al.: The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey. Invest. Ophthalmol. Vis. Sci. (2006) 47:4042-4049.
   PubMed Web of Science ®Google Scholar
• COLLABORATIVE NORMAL-TENSION GLAUCOMA STUDY GROUP: The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am. J. Ophthalmol. (1998) 126:498-505.
   PubMed Web of Science ®Google Scholar
• LICHTER PR, MUSCH DC, GILLESPIE BW et al.: Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial reatment randomized to medications or surgery. Opthalmology (2001) 108:1943-1953.
   PubMed Web of Science ®Google Scholar
• HEIJL A, LESKE MC, BENGTSSON B, HYMAN L, BENGTSSON B, HUSSEIN M: Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch. Ophthalmol. (2002) 120:1268-1279.
   PubMed Web of Science ®Google Scholar
• LESKE MC, HEIJL A, HYMAN L, BENGTSSON B, KOMAROFF E: Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial. Curr. Opin. Ophthalmol. (2004) 15:102-106.
   PubMedGoogle Scholar
• BATEMAN DN, CLARK R,AZUARA-BLANCO A, BAIN M, FORREST J: The effects of new topical treatments on management of glaucoma in Scotland: an examination of ophthalmological health care. Br. J. Ophthalmol. (2002) 86:551-554.
   PubMed Web of Science ®Google Scholar
• WALLAND MJ: Glaucoma treatment in Australia: changing patterns of therapy 1994-2003. Clin. Experiment. Ophthalmol. (2004) 32:590-596.
   PubMed Web of Science ®Google Scholar
• BURR J, AZUARA-BLANCO A, AVENELL A: Medical versus surgical interventions for open angle glaucoma (Review). Cochrane Database Syst. Rev. (2005) 18:CD004399.
   Google Scholar
• TORIS CB, ZHAN G-L, CAMRAS CB, MCLAUGHLIN MA: Effects of travoprost on aqueous humor dynamics in monkeys. J. Glaucoma. (2005) 14:70-73.
   PubMed Web of Science ®Google Scholar
• STJERNSCHANTZ JW: From PGF2α-isopropyl ester to latanoprost: a review of the development of Xalatan. Invest. Ophthalmol. Vis. Sci. (2001) 42:1134-1145.
   PubMed Web of Science ®Google Scholar
• WOODWARD DF, KRAUSS AH-P, CHEN J et al.: The pharmacology of bimatoprost (Lumigan™). Surv. Ophthalmol. (2001) 45(Suppl. 4):S337-S345.
   PubMed Web of Science ®Google Scholar
• ZIAI N, DOLAN JW, KACERE RD, BRUBAKER RF: The effects on aqueous dynamics of PhXA41, a new prostaglandin F2α analogue, after topical application in normal and ocular hypertensive human eyes. Arch. Opthalmol. (1993) 111:1351-1358.
   PubMed Web of Science ®Google Scholar
• BRUBAKER RF, SCHOFF EO, NAU CB, CARPENTER SP, CHEN K, VANDENBURGH AM: Effects of AGN-192024, a new ocular hypotensive agent, on aqueous dynamics. Am. J. Ophthalmol. (2001) 131:19-24.
   PubMed Web of Science ®Google Scholar
• CHRISTIANSEN GA, NAU CB, MCLAREN JW, JOHNSON DH: Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology (2004) 111:1658-1662.
   PubMed Web of Science ®Google Scholar
• TORIS CB, CAMRAS CB, YABLONSKI ME: Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am. J. Ophthalmol. (1999) 128:8-14.
   PubMed Web of Science ®Google Scholar
• SCHAPPERT SM: Office visits for glaucoma: United States, 1991-1992. Adv. Data (1995) 262:1-14.
   PubMedGoogle Scholar
• KONSTAS AGP, MASKALERIS G, GRATSONIDIS S, SARDELLI C: Compliance and viewpoint of glaucoma patients in Greece.Eye (2000) 14:752-756.
   PubMed Web of Science ®Google Scholar
• TAYLOR SA, GALBRAITH SM, MILLS RP: Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study. J. Ocul. Pharmacol. Ther. (2002) 18:401-409.
   PubMed Web of Science ®Google Scholar
• WINFIELD AJ, JESSIMAN D, WILLIAMS A, ESAKOWITZ L: A study of the causes of non-compliance by patients prescribed eyedrops. Br. J. Ophthalmol. (1990) 74:477-480.
   PubMed Web of Science ®Google Scholar
• SLEATH B, ROBIN AL, COVERT D, BYRD JE, TUDOR G, SVARSTAD B: Patient-reported behavior and problems in using glaucoma medications. Ophthalmology (2006) 113:431-436.
   PubMed Web of Science ®Google Scholar
• DASGUPTA S, OATES V, BOOKHART BK, VAZIRI B, SCHWARTZ GF, MOZAFFARI E: Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. Am. J. Manag. Care (2002) 8(10 Suppl.):S255-S261.
   PubMed Web of Science ®Google Scholar
• SPOONER JJ, BULLANO MF, IKEDA LI et al.: Rates of discontinuation and change of glaucoma therapy in a managed care setting. Am. J. Manag. Care (2002) 8(Suppl. 10):S262-S270.
   PubMed Web of Science ®Google Scholar
• DIESTELHORST M, SCHAEFER CP, BEUSTERIEN KM et al.: Persistency and clinical outcomes associated with latanoprost and beta-blocker monotherapy: evidence from a European retrospective cohort study. Eur. J. Ophthalmol. (2003) 13(Suppl. 4):S21-S29.
   PubMed Web of Science ®Google Scholar
• SHAYA FT, MULLINS CD, WONG W, CHO J: Discontinuation rates of topical glaucoma medications in a managed care population. Am. J. Manag. Care (2002) 8(10 Suppl. 10):S271-S277.
   PubMed Web of Science ®Google Scholar
• ROBIN AL, COVERT D: Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology (2005) 112:863-868.
   PubMed Web of Science ®Google Scholar
• PATEL SC, SPAETH GL: Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. (1995) 26:233-236.
   PubMedGoogle Scholar
• TSAI JC, MCCLURE CA, RAMOS SE, SCHLUNDT DG, PICHERT JW: Compliance barriers in glaucoma: a systemic classification. J. Glaucoma (2003) 12:393-398.
   PubMed Web of Science ®Google Scholar
• OLTHOFF CMG, SCHOUTEN JSAG, VAN DE BORNE BW, WEBERS CAB: Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension. Ophthalmology (2005) 112:953-961.
   PubMed Web of Science ®Google Scholar
• ROTER DL, HALL JA, MERISCA R, NORDSTROM B, CRETIN D, SVARSTAD B: Effectiveness of interventions to improve patient compliance: a meta-analysis. Med. Care (1998) 36:1138-1161.
   PubMed Web of Science ®Google Scholar
• HAYNES RB, MCDONALD HP, GARG AX: Helping patients follow prescribed treatment: clinical applications. JAMA (2002) 288:2880-2883.
   PubMed Web of Science ®Google Scholar
• BAUDOUIN C, PISELLA P-J, FILLACIER K et al.: Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology (1999) 106:556-563.
   PubMed Web of Science ®Google Scholar
• CHEN J, DINH T, WOODWARD DF, et al.: Bimatoprost: mechanism of ocular surface hyperemia associated with topical therapy. Cardiovasc. Drug Rev. (2005) 23:231-246.
   PubMedGoogle Scholar
• STJERNSCHANTZ JW, ALBERT DM, HU D-N, DRAGO F, WISTRAND PJ: Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Surv. Ophthalmol. (2002) 47(Suppl. 1):S162-S175.
   PubMed Web of Science ®Google Scholar
• COHEN JS, GROSS RL, CHEETHAM JK, VANDENBURGH AM, BERNSTEIN P, WHITCUP SM: Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv. Ophthalmol. (2004) 49(Suppl. 1):S45-S52.
   PubMed Web of Science ®Google Scholar
• HERNDON LW, WILLIAMS RD, WAND M, ASRANI S: Increased periocular pigmentation with ocular hypotensive lipid use in African Americans. Am. J. Ophthalmol. (2003) 135:713-715.
   PubMed Web of Science ®Google Scholar
• HOYER D, BODDEKE HWGM: Partial agonists, full agonists, antagonists: dilemmas of definition. Trends Pharmacol. Sci. (1993) 14:270-275.
   PubMed Web of Science ®Google Scholar
• CHEN J, SENIOR J, MARSHALL K et al.: Studies using isolated uterine and other preparations show bimatoprost and prostanoid FP agonists have different activity profiles. Br. J. Pharmacol. (2005) 144:493-501.
   PubMed Web of Science ®Google Scholar
• RICHTER M, KRAUSS AH-P, WOODWARD DF, LÜTJEN-DRECOLL E: Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest. Ophthalmol. Vis. Sci. (2003) 44:4419-4426.
   PubMed Web of Science ®Google Scholar
• LÜTJEN-DRECOLL E, TAMM E: Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2α. Exp. Eye Res. (1988) 47:761-769.
   PubMed Web of Science ®Google Scholar
• ZHAN G, TORIS CB, CAMRAS CB, et al.: A prostaglandin DP receptor agonist increases uveoscleral outflow in normotensive monkey eyes. Invest. Ophthalmol. Vis. Sci. (2001) 42:S838.
   Google Scholar
• LIANG Y, LI C, GUZMAN VM, et al.: Comparison of prostaglandin F2α, bimatoprost (prostamide), and butaprost (EP2 agonist) on Cyr61 and connective tissue growth factor gene expression. J. Biol. Chem. (2003) 278:27267-27277.
   PubMed Web of Science ®Google Scholar
• WEINREB RN, KASHIWAGI K, KASHIWAGI F, TSUKAHARA S, LINDSEY JD: Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest. Ophthalmol. Vis. Sci. (1997) 38:2772-2780.
   PubMed Web of Science ®Google Scholar
• NILSSON SFE: The uveoscleral outflow routes. Eye (1997) 11:149-154.
   PubMed Web of Science ®Google Scholar
• WEINREB RN, TORIS CB, GABELT BT, LINDSEY JD, KAUFMAN PL: Effects of prostaglandins on the aqueous humor outflow pathways. Surv. Ophthalmol. (2002) 47(Suppl. 1):S53-S64.
   Web of Science ®Google Scholar
• KHARLAMB AB, WOODWARD DF, BURK RM, HOLOBOSKI M, POSNER M: Ciliary muscle relaxation does not explain the profound ocular hypotension produced by a selective prostanoid EP4 receptor agonist 3,7-dithia PGE1 in monkeys. ARVO (2006):E-Abstract 413.
   Google Scholar
• WAKI M, YOSHIDA Y, OKA T, AZUMA M: Reduction of intraocular pressure by topical administration of an inhibitor of the Rho-associated protein kinase. Curr. Eye Res. (2001) 22:470-474.
   PubMed Web of Science ®Google Scholar
• HONJO M, TANIHARA H, INATANI M et al.: Effects of Rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest. Ophthalmol. Vis. Sci. (2001) 42:137-144.
   PubMed Web of Science ®Google Scholar
• FUKIAGE C, MIZUTANI K, KAWAMOTO Y, AZUMA M, SHEARER TR: Involvement of phosphorylation of myosin phosphatase by ROCK in trabecular meshwork and ciliary muscle contraction. Biochem. Biophys. Res. Comm. (2001) 288:296-300.
   PubMed Web of Science ®Google Scholar
• AMANO M, ITO M, KIMURA K et al.: Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J. Biol. Chem. (1996) 271:20246-20249.
   PubMed Web of Science ®Google Scholar
• KIMURA K, ITO M, AMANO M et al.: Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science (1996) 273:245-248.
   PubMed Web of Science ®Google Scholar
• EUROPEAN GLAUCOMA SOCIETY: Terminology and guidelines for glaucoma (IInd Ed.) Editrice Dogma® Publishing & Communication, Italy (2003).
   Google Scholar
• CANTOR LB: An update on bimatoprost in glaucoma therapy. Expert Opin. Pharmacother. (2002) 3:1753-1762.
   Google Scholar
• WOODWARD DF, PHELPS RL, KRAUSS AH-P et al.: Bimatoprost: a novel antiglaucoma agent. Cardiovasc. Drug Rev. (2004) 22:103-120.
   PubMedGoogle Scholar
• WILLIAMS RD: Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost. Adv. Ther. (2002) 19:275-281.
   PubMed Web of Science ®Google Scholar
• GANDOLFI SA, CIMINO L: Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology (2003) 110:609-614.
   PubMed Web of Science ®Google Scholar
• JÄRVINEN T, PATE DW, LAINE K: Cannabinoids in the treatment of glaucoma. Pharmacol. Ther. (2002) 95:203-220.
   PubMed Web of Science ®Google Scholar